MedTrace Logo

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-03-07

Study results available
· View outcomes & findings →

Summary

To evaluate the potential of DFD-01 (betamethasone dipropionate) Spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Conditions

Interventions

DRUG

DFD01 Spray

DFD-01 (betamethasone dipropionate) Spray, 0.05%

Sponsors & Collaborators

  • Prosoft Clinical

    collaborator OTHER

  • Primus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Srinivas Sidgiddi, MD · Dr. Reddy's Laboratories, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-19
Primary Completion
2019-03-30
Completion
2019-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527421 on ClinicalTrials.gov